LATEST MANUSCRIPTS IN Journal of Immunotherapy and Precision Oncology
Daniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, Michael J Morris, Susan F Slovin, Wassim Abida, Erica D Cohn, Raymond E Baser, Howard I Scher, Karen A Autio. Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.Journal of immunotherapy and precision oncology. 2023, 6 (4): 162-169
Hasan Cagri Yildirim, Fatih Kus, Deniz Can Guven, Ece Karaca, Yunus Kaygusuz, Omer Dizdar, Sercan Aksoy, Mustafa Erman, Suayib Yalcin, Saadettin Kilickap. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab.Journal of immunotherapy and precision oncology. 2023, 6 (4): 170-176
Andrés F Cardona, Vaneza Ávila, Oscar Arrieta. Treatment for Advanced Non-Small Lung Cancer (NSCLC) with Mutated in Low- and Middle-Income Countries (LMICs).Journal of immunotherapy and precision oncology. 2023, 6 (4): 185-186
Lydia Melissourgou-Syka, Michael A Gillespie, Sean M O'Cathail, Owen J Sansom, Colin W Steele, Campbell S D Roxburgh. A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer.Journal of immunotherapy and precision oncology. 2023, 6 (4): 187-197
Daniel Huff, Shannon Fortin Ensign, Margaret S Ryan, Jeanne Palmer, Javier Munoz. Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review.Journal of immunotherapy and precision oncology. 2023, 6 (4): 198-202
. Erratum to "Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature" by Soto et al.Journal of immunotherapy and precision oncology. 2023, 6 (4): 203
Andrea Castro, Aaron M Goodman, Zachary Rane, James V Talwar, Garrett M Frampton, Gerald P Morris, Scott M Lippman, Xinlian Zhang, Razelle Kurzrock, Hannah Carter. Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse.Journal of immunotherapy and precision oncology. 2023, 6 (3): 127-132
Khanh Toan Nguyen, To Ta Van. Treatment of Stage IV Non-Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam.Journal of immunotherapy and precision oncology. 2023, 6 (3): 133-140
Mousa Alali, Maher Saifo. Optimizing the Treatment for Advanced Non-Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review.Journal of immunotherapy and precision oncology. 2023, 6 (3): 140-149
Maluki Radford, Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed. Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era.Journal of immunotherapy and precision oncology. 2023, 6 (3): 150-157
Anca Chelariu-Raicu, Sarina A Piha-Paul, Mariana Chavez-MacGregor, Jason Johnson, Raymond Sawaya, Mary Frances McAleer, Alissa Nguyen, Audrey Hartnett, Apostolia M Tsimberidou, Funda Meric-Bernstam, Ecaterina E Dumbrava. Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.Journal of immunotherapy and precision oncology. 2023, 6 (3): 158-161
Juan I Ruiz, Maria A Lopez-Olivo, Yimin Geng, Maria E Suarez-Almazor. COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review.Journal of immunotherapy and precision oncology. 2023, 6 (2): 103-110
Felipe Soto, Luis F Torre-Sada, Frank E Mott, Sang T Kim, Roza Nurieva, Vickie R Shannon, Saadia A Faiz, Roberto F Casal, Mehmet Altan, Julie Lin, Ajay Sheshadri. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.Journal of immunotherapy and precision oncology. 2023, 6 (2): 111-116
Khalid Balaraj. Abstracts Presented at the 2022 Emirates Oncology Conference: November 25-27, 2022, Abu Dhabi, United Arab Emirates.Journal of immunotherapy and precision oncology. 2023, 6 (2): 117-126